Wenbin Qian

13.2k total citations
170 papers, 2.8k citations indexed

About

Wenbin Qian is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Wenbin Qian has authored 170 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 76 papers in Molecular Biology, 68 papers in Oncology and 65 papers in Hematology. Recurrent topics in Wenbin Qian's work include CAR-T cell therapy research (45 papers), Acute Myeloid Leukemia Research (37 papers) and Virus-based gene therapy research (22 papers). Wenbin Qian is often cited by papers focused on CAR-T cell therapy research (45 papers), Acute Myeloid Leukemia Research (37 papers) and Virus-based gene therapy research (22 papers). Wenbin Qian collaborates with scholars based in China, United States and Madagascar. Wenbin Qian's co-authors include Jie Jin, Liangshun You, Haitao Meng, Xianbo Huang, Wanmao Ni, Wen Lei, Weilai Xu, Xiujin Ye, Junqing Liu and Hongyan Tong and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Cell Biology.

In The Last Decade

Wenbin Qian

162 papers receiving 2.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wenbin Qian China 30 1.4k 997 616 585 429 170 2.8k
Martin E. Dowty United States 24 790 0.6× 799 0.8× 389 0.6× 750 1.3× 479 1.1× 57 3.0k
Astrid Gruber Sweden 34 1.8k 1.3× 927 0.9× 643 1.0× 343 0.6× 251 0.6× 99 3.5k
Jean‐Pierre Bourquin Switzerland 34 2.0k 1.4× 889 0.9× 1.3k 2.1× 522 0.9× 208 0.5× 129 3.9k
Yuho Najima Japan 18 1.0k 0.7× 693 0.7× 834 1.4× 578 1.0× 169 0.4× 98 2.7k
Sumio Sakamaki Japan 28 1.0k 0.7× 924 0.9× 819 1.3× 499 0.9× 489 1.1× 88 3.3k
Jung‐Shin Lee South Korea 31 2.4k 1.7× 1.4k 1.4× 514 0.8× 240 0.4× 194 0.5× 110 4.8k
Priscilla N. Kelly Australia 19 2.5k 1.8× 1.3k 1.3× 618 1.0× 746 1.3× 152 0.4× 92 4.4k
Kah Keng Wong Malaysia 27 1.6k 1.1× 1.3k 1.3× 168 0.3× 506 0.9× 396 0.9× 111 3.7k
Tangsheng Yi United States 24 878 0.6× 1.0k 1.0× 550 0.9× 2.2k 3.7× 240 0.6× 35 3.5k

Countries citing papers authored by Wenbin Qian

Since Specialization
Citations

This map shows the geographic impact of Wenbin Qian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenbin Qian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenbin Qian more than expected).

Fields of papers citing papers by Wenbin Qian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenbin Qian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenbin Qian. The network helps show where Wenbin Qian may publish in the future.

Co-authorship network of co-authors of Wenbin Qian

This figure shows the co-authorship network connecting the top 25 collaborators of Wenbin Qian. A scholar is included among the top collaborators of Wenbin Qian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenbin Qian. Wenbin Qian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lei, Wen, Wenhai Deng, Wenxia Gao, et al.. (2025). Safety and feasibility of 4-1BB co-stimulated CD19-specific CAR-NK cell therapy in refractory/relapsed large B cell lymphoma: a phase 1 trial. Nature Cancer. 6(5). 786–800. 14 indexed citations
2.
3.
Lei, Wen, et al.. (2024). CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy. Blood Advances. 8(11). 2635–2645. 23 indexed citations
4.
Xu, Yang, et al.. (2024). CD27-Armored BCMA CAR T-cell Therapy (CBG-002) for Relapsed and Refractory Multiple Myeloma: A Phase I Clinical Trial. Cancer Immunology Research. 13(1). 23–34. 3 indexed citations
5.
Li, Zengpeng, et al.. (2024). Oncolytic vaccinia virus armed with anti-CD47 nanobody elicit potent antitumor effects on multiple tumor models via enhancing innate and adoptive immunity. Journal for ImmunoTherapy of Cancer. 12(12). e009473–e009473. 8 indexed citations
6.
Lei, Wen, Ai Zhao, Hui Liu, et al.. (2024). Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma. Cell Discovery. 10(1). 5–5. 16 indexed citations
7.
Qian, Wenbin, Hui Liu, Wen Lei, Linqin Wang, & Panpan Chen. (2024). Long-Term Efficacy and Safety of CD19-Specific CAR-T Cells Armed with IL-7 and CCL19 in Patients with Relapsed or Refractory Large B-Cell Lymphoma: A Multi-Center Prospective Study. Blood. 144(Supplement 1). 2087–2087. 1 indexed citations
8.
Hao, Yuanyuan, Panpan Chen, Mengyuan Li, et al.. (2023). Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function of CD19-specific CAR T-cells via TGF-β signaling. Frontiers of Medicine. 18(1). 128–146. 11 indexed citations
9.
10.
11.
Li, Mengyuan, et al.. (2023). Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review. Cancer Biology and Medicine. 20(9). 1–16. 19 indexed citations
12.
Hu, Wei, Ling-Dong Xu, Tong-Tong Zhang, et al.. (2023). T cell proliferation requires ribosomal maturation in nucleolar condensates dependent on DCAF13. The Journal of Cell Biology. 222(10). 6 indexed citations
13.
Lei, Wen, Yuanyuan Hao, Jie Chen, et al.. (2022). CD19-targeted BiTE expression by an oncolytic vaccinia virus significantly augments therapeutic efficacy against B-cell lymphoma. Blood Cancer Journal. 12(2). 16 indexed citations
14.
Wang, Li, Jianda Hu, Wenbin Qian, et al.. (2021). Outcomes in refractory diffuse large B‐cell lymphoma: results from a multicenter real‐world study in China. Cancer Communications. 41(3). 229–239. 17 indexed citations
15.
Li, Xiaolei, Hanren Dai, Xian Li, et al.. (2021). Optimal model establishment of whole-process management data for CAR-T therapy in China—how should this be done?. Cellular and Molecular Immunology. 19(1). 122–124. 1 indexed citations
16.
Lei, Wen, Chaoting Zhang, Chunmei Yang, et al.. (2020). CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1–positive B-Cell Lymphoma. Clinical Cancer Research. 27(2). 473–484. 104 indexed citations
17.
Guo, Yixin, Wenqiang Cao, Wanlu Liu, et al.. (2019). Epigenetic initiation of the T H 17 differentiation program is promoted by Cxxc finger protein 1. Science Advances. 5(10). eaax1608–eaax1608. 21 indexed citations
18.
Tang, Huifen, Hui Zhou, Juying Wei, et al.. (2019). Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma. Hematology. 24(1). 446–454. 11 indexed citations
19.
Xu, Weilai, Yungui Wang, Hongyan Tong, Wenbin Qian, & Jie Jin. (2014). Downregulation of hTERT: An Important As2O3 Induced Mechanism of Apoptosis in Myelodysplastic Syndrome. PLoS ONE. 9(11). e113199–e113199. 7 indexed citations
20.
Jin, Jie, Hui Liu, Chunmei Yang, et al.. (2009). Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation. Molecular Cancer Therapeutics. 8(5). 1387–1397. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Martin E. Dowty Breakdown of academic impact, for papers by Astrid Gruber Breakdown of academic impact, for papers by Jean‐Pierre Bourquin Breakdown of academic impact, for papers by Yuho Najima Breakdown of academic impact, for papers by Sumio Sakamaki Breakdown of academic impact, for papers by Jung‐Shin Lee Breakdown of academic impact, for papers by Priscilla N. Kelly Breakdown of academic impact, for papers by Kah Keng Wong Breakdown of academic impact, for papers by Tangsheng Yi
Rankless by CCL
2026